Post by The Strategic Edge

🚀 AI’s 2026 momentum is accelerating — across medicine, chips, and Wall Street. Early-year moves show one thing clearly: AI is no longer “experimental.” It’s operational. 🏥 Healthcare • MIT revealed a generative AI model to design protein-based drugs, cutting R&D costs for cancer and rare diseases • Weill Cornell Medicine launched “AI to Advance Medicine” for precision cancer and cardiac treatments • AstraZeneca acquired Modella AI to speed oncology trials with in-house pathology models 🧠 Hardware • NVIDIA unveiled the “Vera Rubin” platform at CES 2026 to power trillion-parameter models • AMD launched Ryzen AI 400 chips for local on-device AI • NVIDIA also plans a new inference chip and $2B in optics investments 🏢 Enterprise • Snowflake + OpenAI signed a $200M deal for agentic AI in the Data Cloud • BNY Mellon is deploying 20,000 AI agents • Goldman Sachs and Deutsche Bank are testing AI for real-time trade surveillance 📱 Consumer AI • YouTube rolled out conversational AI on smart TVs • Apple plans a major Siri upgrade using Gemini AI • Samsung targets 800M Gemini-powered devices The pattern: AI is moving from tools → infrastructure → decision-maker. 💬 Strategic question: Which sector will feel AI’s disruption next — logistics, energy, or government? Follow The Strategic Edge for signal-over-noise insights on AI, markets, and policy. #AI #ArtificialIntelligence #HealthTech #Semiconductors #BigTech #EnterpriseAI #AgenticAI #DigitalTransformation #TechTrends #Investing #FutureOfWork